DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma

transcatheter arterial chemoembolization with doxorubicin embedded eluting beads- was performed every 3 weeks through the tumor feeding arteries.

oral use of lenvatinib plus intravenous injection of anti-PD(L)1 antibodies. Anti-PD-L1 antibodies includes duravalumab, atezolizumab, or envolizumab, and anti-PD1 antibodies include pembrolizumab, nivolumab, camrelizumab, tislelizumab, sintilimab, or toripalimab.